Objective To investigate the curative effect of Qingxin Kaiqiao prescription combined with capalatine in the treatment of mild and moderate Alzheimer's disease with Phlegm turbidity-mongolian orifice syndrome.Methods A total of 80 mild to moderate AD patients who were admitted to our hospital from July 2021 to July 2023 were randomly divided into the observation group(40 patients)and the control group(40 patients).The control group treated with capalatine,while the observation group received treatment with Qingxin Kaiqiao prescription combined with capalatine.After 2 months of continuous treatment,the clinical efficacy,Montreal cognitive assessment scale(MoCA)scores,mini mental state examination(MMSE)scores,daily life scale(ADL)scores and traditional Chinese medicine(TCM)syndrome points of the two groups were compared.Results The total effective rate of the observation group was 90%,higher than the control group(72.5%)(P<0.05).After treatment,the MMSE,MoCA and ADL scores of the two groups were higher than before treatment(P<0.05),and the observation group was higher than the control group(P<0.05).After treatment,the TCM syndrome scores of the two groups were lower than before treatment(P<0.05),and the observation group was lower than the control group(P<0.05).Conclusion Qingxin Kaiqiao prescription combined with capalatine has a significant effect on the treatment of mild to moderate AD with Phlegm turbidity-mongolian orifice syndrome,which can further improve clinical efficacy,cognitive function and daily living ability of patients.
Qingxin Kaiqiao PrescriptionCapalatineAlzheimer's DiseasePhlegm turbidity-mongolian orifice syndromeCognitive function
万方数据
维普
